Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort.
Laetitia ColletLauriane EberstGauthier LudovicMarc DebledLoana HrabMarie-Ange Mouret-ReynierIsabelle DesmoulinsAnthony GoncalvesMario CamponeJean-Marc FerreroEtienne BrainLionel UwerJean-Christophe EymardVeronique DierasGaetane SimonMarianne LeheurteurFlorence DalencLaurence VanlemmensAmelie DarlixMonica ArnedosThomas BachelotPublished in: Breast cancer (Tokyo, Japan) (2023)
In this real-life cohort, trastuzumab-pertuzumab continuation after local treatment for isolated CNS progression did not negatively impact PFS and OS. Prospective trials and assessment of new strategies are warranted in this specific situation.